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resistance training, it does show that quadriceps resistance
training during a severe exacerbation of COPD can (1) prevent
discharge of patients with muscle function worse than that which
they had at admission, and (2) assist such patients in maintaining
function during and possibly after the exacerbation phase. Also,
even though only the quadriceps muscles were targeted for
training, one can speculate that similar training for different
muscles would yield comparable results.
This interesting study may have practical consequences for the
hospital management of acute COPD exacerbation, beyond usual
medical therapy. First, it restores the importance of a nonphar-
macological therapy at the earliest onset of disability. Second, it
emphasizes the role of physical therapy in the acute hospital
setting. However, a study of the same protocol in a more severely
ill population (e.g., in patients suffering from respiratory in-
sufficiency, who are more likely to be hospitalized) should be
performed to confirm both the feasibility and the effectiveness of
this training strategy.
It would have been interesting if the authors had explored
recovery of daily activities, which is a direct consequence of
better muscle function. Indeed, a rehabilitation course including
limb training may positively influence this outcome in severely
ill patients (14, 15). Future research in patients with COPD
exacerbations should highlight this point, thus conveying an
even more powerful message to practitioners.
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A Continuum of Ion Transport Dysfunction or Multiple Hits?
Bronchiectasis, a syndrome characterized by chronic cough with
purulent sputum and bronchial dilation involving more than one
lobe on computed tomography scans, remains in many cases
a pathophysiological dilemma. Bronchiectasis is often considered
to result from a failure of lung defense that leads to chronic airway
infection, airway wall damage, and airway ectasia. In this issue of
the Journal (pp. 1078–1084), Bienvenu and colleagues investigate
the pathogenesis of bronchiectasis in a large cohort of subjects in
whom known causes of bronchiectasis were thought to have been
excluded (1).
In their study, Bienvenu and colleagues focus on the potential
role of abnormal airway ion transport, as indexed by the nasal
potential difference (PD) measurement, in the pathogenesis of
the bronchiectatic phenotype, focusing on the role of abnormal
cystic fibrosis transmembrane regulator (CFTR) function in
governing ion transport rates. Thus, a combination of nasal PD
measurements, molecular assessments of CFTR mutation status,
sweat Cl2 concentrations, and clinical indices, including bacterial
colonization and FEV1, were measured and correlated. The
groups were broken down into subjects with bronchiectasis ex-
hibiting no CFTR mutations or sequence variants (DB0, 85
subjects), those with a single CFTR mutation or sequence variant
(DB1, 22 subjects), and patients with two CFTR mutations or
variants (DB2, 15 patients).
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As a group, the subjects with bronchiectasis had evidence of
abnormal ion transport. The degree of abnormality correlated
with the number of CFTR mutations or sequence variants, that is,
0, 1, or 2. Although still subject to debate, there appears to be an
emerging consensus that the abnormal ion transport defects in CF
reflect abnormalities in both the Na1 absorptive and Cl2
secretory processes that regulate airway surface hydration (2).
It appears that abnormal airway surface hydration in CF leads to
collapse of the periciliary layer, adhesion of a concentrated mucus
layer to airway surfaces, persistent mucus, bacterial infection,
inflammation, and lung damage, including diffuse bronchiectasis.
Several key physiological concepts have emerged to explain
certain clinical features of CF, including the long periods of
relative health during basal states and the profound effects of
acute exacerbations on lung function. The first concept is that CF
lung disease indeed reflects a vulnerability to exogenous insults
that trigger intercurrent exacerbations rather than a persistent
failure of lung defense (3). A second concept is that the
vulnerability to transient losses of lung defense is a function of
(1) the severity of the CFTR mutations, and (2) modifier genes
and environmental influences, both socioeconomic and viral/
inhaled pollutant exposures (4, 5). Analyses of both the severity
of CFTR mutations and potential modifier gene/environmental
influences are instructive in identifying mechanisms relating the
postulated continuum of ion transport dysfunction to disease
phenotype in the Bienvenu and colleagues bronchiectasis cohort.
The patients described with two CFTR mutations or se-
quence variants (DB2 patients) as a group had intermediate
sweat Cl2 values and nasal PD values just outside the range
diagnostic for CF, and 11 of 15 had bacterial colonization with
organisms typical of CF. Thus, these patients were likely
correctly assigned to a ‘‘CF’’ or ‘‘CF-related disease’’ category,
and the relatively mild phenotype likely reflected the mild
nature of the CFTR mutations or sequence variants per se and
potentially contributions of modifier genes and/or environmen-
tal influences.
The DB1 subjects with bronchiectasis, with a single genetically
identified CFTR mutation or sequence variant, exhibited nasal
ion transport defects intermediate between those of patients with
bronchiectasis with two versus no CFTR mutations/variants, and
importantly, bioelectric properties different from those of phe-
notypically ‘‘normal’’ CFTR obligate heterozygotes. Because the
entire CFTR gene was not sequenced in this study, some of these
DB1 subjects indeed may have had an unrecognized second
CFTR mutation to account for the differences in nasal PDs from
obligate CFTR heterozygotes. In parallel, modifier genes, in-
cluding mutations in the epithelial sodium channel gene (ENaC),
and environmental influences, for example, respiratory viruses
and acid reflux, may play a role in producing the bioelectric and
clinical phenotype characteristic of this subgroup.
The most interesting patient population was that of the
bronchiectatic patients who exhibited no defined mutations in
CFTR and nasal PD patterns consistent with abnormal Na1
transport but normal Cl2 transport (DB0 patients). It is possible
that the raised Na1 transport rates were an acquired phenotype in
response to chronic inflammation and infection, although the
typical pattern is for reduced Na1 transport rates in this setting
(6). Consequently, it is possible that in these patients, genetic
abnormalities in ENaC-mediated Na1 transport may contribute
to disease pathogenesis, as has been previously suggested by
Fajac and colleagues (7). As the trend in this bronchiectatic
subpopulation is for raised nasal PDs and raised amiloride-
sensitive PDs (Damiloride PDs), the ENaC mutations presum-
ably reflect a gain-of-function phenotype. Lessons from another
gain-of-function ENaC mutation, that is, that associated with
Liddle’s syndrome, suggest that this mutation produces a pheno-
type in which the Liddle’s ENaC hyperfunction expressed in the
kidney is suppressed by CFTR in the respiratory tract, likely
explaining the absence of a respiratory phenotype in patients with
Liddle’s syndrome (8, 9). Thus, disease-causing ENaC mutations
in this bronchiectasis subpopulation might be predicted to be
ones that escape CFTR regulation. It should be noted that the
abnormality in ENaC associated with CF lung disease is not the
absolute rate of ENaC-mediated Na1 transport, but the failure of
ENaC-mediated Na1 absorption to slow as the airway surface
becomes dehydrated (volume depleted). This observation sug-
gests that airway surface liquid volume measurements may best
assess ENaC mutations in the context of causing airway disease
(2).
Perhaps equally interesting is the fact that many of the DB0
patients have nasal Na1 transport and Damiloride PDs that
overlap the normal range, raising a question concerning why
normal subjects in this range did not exhibit disease. This question
raises the possibility that ‘‘multiple hits’’ in lung defense are
required to produce disease in this subpopulation as well as
others. For example, it has been reported that bENaC mice (mice
expressing a bENaC transgene), exhibiting a gain of function in
airway Na1 transport and a pulmonary disease phenotype that
resembles CF, do not exhibit a spontaneous airway bacterial
infection in adulthood (10). However, when bENaC mice are
bred with mice that have a second genetic defect in lung defense
that also does not produce spontaneous bacterial infection, for
example, a genetic deletion of the MyD88 signaling molecule that
couples bacterial LPS production to airway luminal neutrophilia,
a persistent bacterial infection results in double-mutant mice
(11). Thus, it may be instructive in the DB0 patient population to
look specifically for modifier genes/second genetic mutations in
pathways that are complementary to the mucus clearance path-
way in keeping the airway free of bacterial pathogens.
The article by Bienvenu and colleagues also raises three
other questions regarding patients with bronchiectasis.
First, are nasal PDs diagnostically useful in this disease group?
As the authors argue, although nasal PDs are not part of the
currently designated diagnostic workup for CF (12), they appear
to be useful in this patient population, including both individual
Na1 versus Cl2 transport parameters and combined indices.
Indeed, both Bienvenu and colleagues (1) and Wilschanski and
colleagues (13) use diagnostic indices that include the Damiloride
response as the index of Na1 transport, and indices of Cl2
transport that include the Disoproterenol PD (Diso) and DCl2
free PD/Diso response, respectively. However, it should noted
that the Damiloride response measures not only the inhibition of
Na1 transport by amiloride but also the capacity of the epithelium
to increase Cl2 secretion in response to the hyperpolarization of
the cell interior caused by the amiloride block of ENaC (14).
Consequently, the Damiloride response is somewhat redundant
for measuring Cl2 transport with 0 Cl2/0 Cl2 Diso measurements.
Indeed, the basal PD is perhaps a better index of Na1 transport
rates alone (14), so perhaps a combination of the basal PD plus
the total Cl2 permeability response, as revealed by the sum of the
D0 Cl2 and DIso responses, may be even more discriminative.
Second, is chronic bacterial infection a typical feature of
bronchiectasis? The DB2 patients had a relatively high incidence
of bacterial colonization (11 of 15), but the DB1 patients (6 of 22)
and the DB0 patients had a relatively low incidence of culture-
defined bacterial colonization. This result suggests two quite
different possibilities. It is possible that this failure to identify
bacterial pathogens reflects the relative insensitivity of classic
bacterial hospital cultures to detect the spectrum of bacteria that
chronically infect the abnormal lung, as suggested by compari-
sons of cultures with culture-independent 16S profiling in CF (15).
Alternatively, this result could suggest that our current under-
1018 AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE VOL 181 2010
 
standing of the pathogenesis of bronchiectasis is poor and that
processes that directly damage the airway wall may be more
important in the bronchiectatic phenotype than chronic infection.
Certainly, the results of culture-independent molecular profiling
of bacterial species in bronchiectatic patient populations will be
important, both for research and for clinical applications.
Finally, are we treating our patients with bronchiectasis
optimally? As noted previously, an accurate description of the
microbiological communities that may inhabit the bronchiectatic
lung will be important to tailor antibiotics. From a broader view,
the notion that abnormal ion transport produces a dehydrated
airway surface in bronchiectasis, with chronic mucus adhesion
and infection, suggests that agents that restore hydration to
airway surfaces may be rational for this patient population.
Indeed, ‘‘hydrating’’ agents such as inhaled hypertonic saline
and other osmolytes appear to be efficacious in subjects with CF
(16, 17). Thus, studies of the pathogenesis of bronchiectasis, based
on principles of electrolyte transport abnormalities and the
spectrum of microbial infections gleaned from CF, may spur
a new wave of therapies for bronchiectatic patients that may be
more effective in controlling bronchiectatic symptoms and, we
hope, eradicating the progression of this disease.
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